Our team has been very busy utilizing our proprietary data mining techniques and sophisticated algorithms to analyze post – market drug side effect data this year and our work has not gone unnoticed. Our findings have been showcased in FiercePharma, MedScape, Drug Discovery & Development, Heathline, and much more!

Check out all our featured articles here

To make sure that 2015 gets off to a good start, we are listing our top 10 downloads of 2014. They are free to download, just fill in a quick form. Download one or download them all, we hope you enjoy!

 

1.) Special Report: Multiple Sclerosis

The Comparative Safety of Multiple Sclerosis Medications: An Analysis Utilizing AdverseEvents Explorer

The comparative safety of older-generation drugs, such as interferons vs.newer drug regimens and which drugs have the best and worst overall safety profiles compared to their peers.

Download Now

 

2.) Special Report: Type 2 Diabetes

The Comparative Safety of Type 2 Diabetes Medications: An Analysis Utilizing AdverseEvents Explorer

Assess comparative safety research within and across classes of drugs and review the clinical and post-approval safety information available for Type 2 Diabetes Drugs

Download Now

 

3.) Special Report: January FOIA Request

Expediating Drug Safety Using FOIA: An Analysis of 57,000 New Unreleased FAERS Reports

AdverseEvents filed a Freedom of Information Act (FOIA) request with the Food and Drug Administration to receive updated drug side effect reports on 105 key drugs. These key drugs included all new drugs approved on or after January 1, 2011 as well as all of the drugs that were already on our Active RxSignal alert watch list. Using text-mining methods, we were able to extract 57,158 new primary suspect cases for our target drug list.

Download Now

 

4.) Special Report: Obesity Drug - Contrave

Comparative Analysis of the Newly Approved Obesity Drug: Contrave

Report highlights some of the safety considerations for currently approved obesity treatments as well as compare the safety profiles of Contrave and Qsymia.

Download Now

 

5.) Special Report: Cholesterol Lowering - Statin

The Comparative Safety of Cholesterol Lowering (Statin) Medications: An Analysis Utilizing AdverseEvents Explorer

A discussion surrounding the controversy between possible links between statin treatment and diabetes and which two specific drugs have an elevated risk

Download Now

 

6.) Special Report: Blood Thinners

Examining the Comparative Safety of Blood Thinners: An Analysis Utilizing AdverseEvents Explorer

A discussion surrounding the controversy between possible links between statin treatment and diabetes and which two specific drugs have an elevated risk

Download Now


7.) Special Report: September FOIA Request

Expediting Drug Safety Using FOIA: An Analysis of 48,971 Unreleased FAERS Reports

AdverseEvents has filed Freedom of Information Act (FOIA) requests for 152 individual drugs, for which the FDA has provided 88,922 pages of unstandardized data, in PDF format. We were able to extract 48,971 new primary suspect cases

Download Now

 

8.) Special Report: Hepatitis C

The Comparative Safety of Hepatitis C Medications: An Analysis Utilizing AdverseEvents Explorer

A detailed examination of post-marketing side effect data from both newer, and older, Hepatitis C medications.

Download Now

 

9.) Whitepaper: Post FDA approval drug safety data

Post FDA-approval drug safety data: why they are vital and how they can be made accessible, actionable, and predictable.

Due to financial and logistical hurdles, no pre-approval clinical trial can ever be large enough, or long enough, to identify and properly characterize all side effects that may occur once a drug is introduced to large consumer populations.

Download Now

 

10.) Published Research: Stimulated Reporting

Stimulated Reporting: The Impact of US Food and Drug Administration-Issued Alerts on the Adverse Event Reporting System (FAERS)

“Stimulated reporting,” is the concept that public disclosure of a safety issue by the issuance of an FDA alert or warning, or the clustering of adverse event reports triggered by consumer-based “support group” and/or litigation, will result in substantially increased reporting rates for the affected drug. links between statin treatment and diabetes and which two specific drugs have an elevated risk

Download Now

 

Make sure you check out our top blog posts of the year - 2014: The year of data minions, drug safety hipsters, and scarface

 

For even more reports, check out our RESOURCE CENTER

 

 Subscribe to Drug Safety Monitor


Kerry Anne Fraser

Kerry Anne Fraser

Inbound Marketing Specialist

Kerry Fraser Linkedin

Jim Davis

Written by Jim Davis

As Executive Vice President, Jim is responsible for the commercialization strategy for Advera Health Analytics.